Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.67 USD
0.89%
Market Closed
Updated:
May 5, 2024
P/B
Price to Book Value
Price to Book Value
1.3
Current
2.1
Median
2.6
Industry
Lower
than median
Lower
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=1.3
Market Cap
/
463.6m
Book Value of Equity
349.1m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
463.6m USD | 1.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 27.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 26.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 5.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 5.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 4.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 3.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 16.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 2.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 2.3 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
